Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

LON/0RC7 stock hub

LON/0RC7 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LON/0RC7is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

230.9M

London Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

LON/0RC7

In the news

Latest news · LON/0RC7

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.9P50 16.9P75 23.5

Trailing P/En/a

P25 15.9P50 22.9P75 35.8

ROEn/a

P25 -54.2P50 2.1P75 13.7

ROIC-56.5

P25 -38.1P50 3.3P75 11.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LON/0RC7 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

159

Groups with data

Currency

SEK

Showing 159 of 159 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Sweden
Country code	UK
Employees	122
Employees Change	-2%
Employees Change Percent	-1.48
Enterprise value	SEK 268M
Exchange	London Stock Exchange
Financial currency	SEK
First seen	2026-05-10
Industry	Biotechnology
Last refreshed	2026-05-10
Market cap	SEK 230.9M
Price	SEK 28.7
Price currency	SEK
Rev Per Employee	124,246.72x
Sector	Healthcare
Sic	2836
Symbol	lon/0RC7
Website	https://www.hansabiopharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-23.83%
EV Earnings	-4.87x
EV/Sales	17.68x
P/B ratio	-10.54x
P/S ratio	15.23x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-299.37%
EBITDA Margin	-298.07%
Gross margin	59.67%
Gross Profit	SEK 9M
Gross Profit Growth	18.68%
Gross Profit Growth Q	-54.64%
Gross Profit Growth3 Y	0.63%
Gross Profit Growth5 Y	57.03%
Net Income	SEK -55M
Pretax Margin	-361.81%
Profit Per Employee	SEK -451,091
ROA	-38.17
Roa5y	-33.49
ROCE	-60.45
ROIC	-56.51

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-3.57%
Cagr1y	11.16%
Cagr3y	-18.73%
Cagr5y	-28.11%
Revenue Growth	4.85x
Revenue Growth Q	-47.9x
Revenue Growth Quarters	2x
Revenue Growth3 Y	8.67x
Revenue Growth5 Y	68.05x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	SEK 0.2
Assets	SEK 92.5M
Cash	SEK 53.8M
Current Assets	SEK 63.2M
Current Liabilities	SEK 17.4M
Debt	SEK 90.9M
Equity	SEK -21.9M
Interest Coverage	-2.55
Liabilities	SEK 114.4M
Long Term Assets	SEK 29.3M
Long Term Liabilities	SEK 97M
Net Cash	SEK -37.1M
Net Cash By Market Cap	SEK -16.05
Tangible Book Value	SEK -40.5M
Tangible Book Value Per Share	SEK -0.4
WACC	13.89

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.63
Inventory Turnover	17.2
Net Working Capital	SEK -7.5M
Quick ratio	3.6
Working Capital	SEK 45.8M
Working Capital Turnover	SEK 0.04

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-34.63%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-30.49%
1Y total return	11.16%
200-day SMA	32.01
3Y total return	-46.33%
50-day SMA	29.78
50-day SMA vs 200-day SMA	50under200
5Y total return	-80.79%
All Time High	349
All Time High Change	-91.78%
All Time High Date	2018-10-03
All Time Low	20.1
All Time Low Change	42.79%
All Time Low Date	2025-04-07
ATR	0.98
Beta	1.64
Ch YTD	-14.03
High	28.7
High52	42.96
High52 Date	2025-10-01
High52ch	-33.19%
Low	28.7
Low52	23.06
Low52 Date	2025-05-30
Low52ch	24.46%
Ma50ch	-3.62%
Price vs 200-day SMA	-10.34%
RSI	49.49
RSI Monthly	44.24
RSI Weekly	45.75
Sharpe ratio	0.31x
Sortino ratio	0.55
Total Return	-34.63%
Tr YTD	-14.03
Tr1m	-4.2%
Tr1w	3.6%
Tr3m	-19.74%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	SEK -45.4M
Operating margin	-299.4

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	74,057,974%
Net Borrowing	9,245,315.3
Shares Insiders	6.12%
Shares Institutions	21.68%
Shares Qo Q	0%
Shares Yo Y	34.63%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	5,597.9x
Bv Per Share	-0.22
Ch10y	-30.49
Ch1m	-4.2
Ch1w	3.6
Ch1y	11.16
Ch3m	-19.74
Ch3y	-46.33
Ch5y	-80.79
Ch6m	5.3
Change	-0.69%
Change From Open	1.34
Close	28.9
Days Gap	-2.01
Depreciation Amortization	198,228.7
Dollar Volume	4,592
Earnings Date	2026-07-16
EBIT	SEK -45.4M
EBITDA	SEK -45.2M
EPS	SEK -0.61
F Score	3
Financing CF	78,132,101
Fiscal Year End	December
Founded	2,007
Income Tax	SEK 189,709
Is Primary Listing	0
Last Earnings Date	2026-03-26
Last Report Date	2026-03-31
Ma150	32.38
Ma150ch	-11.35%
Ma20	28.23
Ma20ch	1.66%
Net CF	33,920,194
Next Earnings Date	2026-07-16
Open	28.32
Ppne	848,869.5
Price Date	2026-05-08
Relative Volume	0.03x
Revenue	15,158,100x
SBC By Revenue	18.26x
Share Based Comp	2,768,208
Tax By Revenue	1.25x
Tr6m	5.29%
Volume	160

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does LON/0RC7 pay a dividend?

Capital-return profile for this ticker.

Performance

LON/0RC7 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns LON/0RC7?

Insider, institutional, and short-interest positioning.

Institutional ownership

+21.7%

Share of float held by funds and institutions

Insider ownership

+6.1%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+34.6%

Negative means the company is buying back shares.

Technical

LON/0RC7 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

49.5

Neutral momentum band

Price vs 200-day MA

-10.3%

50/200-day relationship not available

Beta (5Y)

1.64

More volatile than the market

Sharpe ratio

0.31

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LON/0RC7

Hub-level FAQ points readers to the deeper analysis pages.

What is the current lon/0RC7 stock rating?

lon/0RC7 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full lon/0RC7 analysis?

The full report lives at /stocks/lon/0RC7/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for lon/0RC7?

The latest report frames lon/0RC7 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the lon/0RC7 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.